Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma 85Lymphoma 58Lymphoma, Large B-Cell, Diffuse 55Lymphoma, Non-Hodgkin 34Osteosarcoma 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Hodgkin Disease 25Burkitt Lymphoma 24Testicular Neoplasms 22Neuroectodermal Tumors, Primitive, Peripheral 19Ovarian Neoplasms 18Leukemia 18Lymphoma, Follicular 17Fibrosarcoma 16Testicular Germ Cell Tumor 15Neuroblastoma 15Teratoma 14Rhabdomyosarcoma 14Lymphoma, Large-Cell, Immunoblastic 14Liposarcoma 14Lymphoma, Mantle-Cell 13Lymphoma, Large-Cell, Anaplastic 13Hemangiosarcoma 13Recurrence 12Neurofibrosarcoma 12Leiomyosarcoma 12Histiocytoma, Malignant Fibrous 12Central Nervous System Neoplasms 12Sarcoma, Synovial 11Lymphoma, B-Cell, Marginal Zone 11

Interventions

Lenalidomide 4Gemcitabine 4Dexamethasone 4Cyclophosphamide 4Bortezomib 4Nivolumab 3Cisplatin 3Carboplatin 3vandetanib 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2pomalidomide 2pembrolizumab 2liposomal doxorubicin 2fludarabine 2durvalumab 2capivasertib 2Radiosurgery 2Paclitaxel 2Doxorubicin 2Bevacizumab 2Anthropogenic Effects 2venetoclax 1umbralisib 1ublituximab 1tremelimumab 1tivozanib 1ricolinostat 1regorafenib 1pazopanib 1niraparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × Ifosfamide × Clear all
NCT04044378 2020-05-19

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Peking University People's Hospital

Phase 1/2 Withdrawn

Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡